Citizens reiterated its Market Outperform rating on Kura Oncology Inc. (NASDAQ: KURA) on Tuesday, maintaining a price target of $24.00 per share. The firm highlighted the biotechnology company’s recent operational progress and financial performance as key drivers behind the bullish stance.
Kura reported second-quarter 2026 adjusted loss per share of $0.77, beating analyst expectations of an $0.88 loss. Revenue totaled $20.87 million, exceeding the $20.16 million forecast. The company’s cash position stood at $519 million, with a current ratio of 4.73.
Analysts noted that the revenue beat was supported by initial commercial sales of Kura’s new oncology drug, KOMZIFTI. The company also reported capturing the majority of new treatment starts for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML) using its lead candidate, ziftomenib. Multiple registration studies for ziftomenib are currently underway, with updated combination data expected to be presented at the American Society of Hematology (ASH) conference.
Citizens’ price target implies a 102% upside from the stock’s closing price of $11.89 on Tuesday. The firm also outlined a range of potential scenarios, with a pessimistic case projecting $5 per share and an optimistic case reaching $30. The broader analyst consensus remains strongly bullish, with a price target range of $15 to $76.
Kura President and CEO Troy Edward Wilson purchased 100,000 ordinary shares at a weighted average price of $11.12 per share, reflecting insider confidence in the company’s trajectory.
